Contract Farming Service & Inducing Regulator by Mother Agri Biotech Laboratories India Pvt. Ltd.

| September 23, 2015

article image
Mother Agri Biotech Laboratories India Private Limited aim to satisfy the demands of our customers from farming industry. Company came into existence in the year 2012, We are engaged in the manufacturing and supplying of products such as Tissue Cultured Teak Plant, Agricultural Fertilizer and Inducing Regulator and many more. We are also known to provide several services like Contract Farming Service, Plant Tissue Culture Training, Plantation Consultancy Service and many more. Due to our ethical business practices and customer centric philosophy, we are constantly engaged in serving our clients with most optimum solutions. We have successfully flourished a rich customer base across the nation. In fostering a smooth growth in organization, our pool of workforce has helped us a lot by contributing their efforts in terms of hard work and dedication. We have hired a big team of workers who go through a series of tasks in accordance to their capability. They cordially manage tasks and always work as per the requirement of the customer. With their immense support, we have become able to earn a position of envy in the industry.

Spotlight

Bio-X (S) Pte. Ltd

Bio-X(S) Pte. Ltd. Is a Signapore startup that has received a mix of public and private funding in order to commercialize a new, highly sensitive ISFET chip-based chemical reaction sensor developed in Japan.

OTHER ARTICLES

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

Ruminating on Bioprocessing 4.0

Article | February 18, 2020

The Bioprocessing 4.0 concept seeks to apply automation and technology to the digital transformation of biologics manufacturing. As the paradigm moves forward, it faces barriers to its adoption, according to Eric Langer, president of BioPlan Associates. “Perhaps the greatest challenges involve unsecured links and adapting the applications to areas where automation is critically needed today,” says Langer. “Unresolved security issues could seriously affect a company’s data in a regulated environment, so they will need to have iron-clad anti-hacking protection in place. Unfortunately, cyber security is not yet a top focus for the industry.”

Read More

Making Predictions by Digitizing Bioprocessing

Article | April 20, 2021

With advances in data analytics and machine learning, the move from descriptive and diagnostic analytics to predictive and prescriptive analytics and controls—allowing us to better forecast and understand what will happen and thus optimize process outcomes—is not only feasible but inevitable, according to Bonnie Shum, principal engineer, pharma technical innovation, technology & manufacturing sciences and technology at Genentech. “Well-trained artificial intelligence systems can help drive better decision making and how data is analyzed from drug discovery to process development and to manufacturing processes,” she says. Those advances, though, only really matter when they improve the lives of patients. That’s exactly what Shum expects. “The convergence of digital transformation and operational/processing changes will be critical for the facilities of the future and meeting the needs of our patients,” she continues. “Digital solutions may one day provide fully automated bioprocessing, eliminating manual intervention and enabling us to anticipate potential process deviations to prevent process failures, leading to real-time release and thus faster access for patients.” To turn Bioprocessing 4.0 into a production line for precision healthcare, real-time release and quickly manufacturing personalized medicines will be critical. Adding digitization and advanced analytics wherever possible will drive those improvements. In fact, many of these improvements, especially moving from descriptive to predictive bioprocessing, depend on more digitization.

Read More

Spotlight

Bio-X (S) Pte. Ltd

Bio-X(S) Pte. Ltd. Is a Signapore startup that has received a mix of public and private funding in order to commercialize a new, highly sensitive ISFET chip-based chemical reaction sensor developed in Japan.

Events